TUG1 and glioblastoma: In glioblastoma, intravenous treatment with ASOs targeting TUG1, in conjunction with a sophisticated drug delivery system, induces GSC differentiation and efficiently inhibits GSC growth in vivo, indicating that TUG1 may be a potent therapeutic approach to eradicate the GSC population (Katsushima et al., 2016).